Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)
-
Published:2024-06
Issue:
Volume:18
Page:100674
-
ISSN:2666-6677
-
Container-title:American Journal of Preventive Cardiology
-
language:en
-
Short-container-title:American Journal of Preventive Cardiology
Author:
Razavi Alexander C.ORCID,
Richardson LaTonia C.,
Coronado Fátima,
Dzaye Omar,
Bhatia Harpreet S.,
Mehta Anurag,
Quyyumi Arshed A.,
Vaccarino Viola,
Budoff Matthew J.,
Nasir Khurram,
Tsimikas Sotirios,
Whelton Seamus P.,
Blaha Michael J.,
Blumenthal Roger S.,
Sperling Laurence S.ORCID
Reference16 articles.
1. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease;Arnett;J Am Coll Cardiol,2019
2. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular Disease in 2019: the MESA study (multi-ethnic study of atherosclerosis);Cainzos-Achirica;Circulation,2020
3. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association;Reyes-Soffer;Arterioscler Thromb Vasc Biol,2022
4. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes;Lacaze;J Am Coll Cardiol,2022
5. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy;Chasman;Atherosclerosis,2009
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献